JPMorgan upgrades Constellium to Overweight and raises price target to $35 after Q3 earnings beat

Constellium reported Q3 2026 adjusted EBITDA of $280 million, beating estimates by 12%. JPMorgan upgraded the stock from Neutral to Overweight, lifting its price target from $34 to $35 and raising fiscal 2026 EBITDA guidance by 5% to a range of $1.03 billion‑$1.06 billion. The firm also reaffirmed free cash flow guidance of more than $300 million. The upgrade came despite the stock falling about 1.2% on the day.

JPMorgan's new $35 target implies roughly a 45.7% upside from the $24.02 close, which could attract buying pressure. The higher EBITDA guidance may improve earnings expectations for fiscal 2026.

  • 1Constellium posted Q3 2026 segment adjusted EBITDA of $280 million, 12% above consensus.
  • 2JPMorgan upgraded Constellium to Overweight from Neutral and raised its price target to $35 from $34.
  • 3Fiscal 2026 EBITDA guidance was increased by 5% to a range of $1.03 billion‑$1.06 billion.
  • 4The company reaffirmed fiscal 2026 free cash flow guidance of more than $300 million.
  • 5Third‑quarter free cash flow totaled $128 million.
  • 6Net leverage stood at 1.6 times.

Sources